WP
NEUP

Woodline Partners’s Neuphoria Therapeutics NEUP Stock Holding History

Woodline Partners’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,537
Closed -$120K – 768
2023
Q2 		$120K Sell
4,537
-62
-1% -$1.72K ﹤0.01% 605
2023
Q1 		$143K Sell
4,599
-7,065
-61% -$298K ﹤0.01% 603
2022
Q4 		$651K Sell
11,664
-87
-0.7% -$7.55K 0.01% 582
2022
Q3 		$884K Hold
11,751
– – 0.01% 546
2022
Q2 		$986K Sell
11,751
-1,661
-12% -$162K 0.02% 511
2022
Q1 		$1.37M Sell
13,412
-83
-0.6% -$10.9K 0.02% 446
2021
Q4 		$2.03M Buy
+13,495
New +$2.07M 0.03% 413

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
APC
Aspire Private Capital Cornelius, North Carolina $484M AUM 17.28% 1-Year Est. Return

Woodline Partners's NEUP Position: Q3 2023 in Review

Woodline Partners sold out of Neuphoria Therapeutics (NEUP) in Q3 2023, closing a stake of 4,537 shares — an estimated $120K sold.

Woodline Partners first reported a position in NEUP in Q4 2021 and held it in 7 quarters. The position peaked at $2.03M in Q4 2021. 11 funds tracked by Wall St. Rank hold NEUP as of Q3 2023.

  • Woodline Partners reported no remaining Neuphoria Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Woodline Partners sold 4,537 Neuphoria Therapeutics shares in Q3 2023, an estimated $120K.
  • Woodline Partners first reported a position in Neuphoria Therapeutics in Q4 2021 and held it in 7 quarters.
  • Woodline Partners's Neuphoria Therapeutics position peaked at $2.03M in Q4 2021.
  • 11 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q3 2023.

Based on Woodline Partners's 13F filing for Q3 2023, filed 14 Nov 2023.